These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23094060)

  • 1. Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China.
    Zhang M; Jiao Y; Wang S; Zhang L; Huang Z; Chen Y; Wu H
    PLoS One; 2012; 7(10):e47548. PubMed ID: 23094060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.
    deCamp A; Hraber P; Bailer RT; Seaman MS; Ochsenbauer C; Kappes J; Gottardo R; Edlefsen P; Self S; Tang H; Greene K; Gao H; Daniell X; Sarzotti-Kelsoe M; Gorny MK; Zolla-Pazner S; LaBranche CC; Mascola JR; Korber BT; Montefiori DC
    J Virol; 2014 Mar; 88(5):2489-507. PubMed ID: 24352443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
    Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
    J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors.
    Sapsutthipas S; Tsuchiya N; Pathipavanich P; Ariyoshi K; Sawanpanyalert P; Takeda N; Isarangkura-na-ayuthaya P; Kameoka M
    PLoS One; 2013; 8(1):e53920. PubMed ID: 23308290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitope specificity of cross-clade neutralizing sera from Chinese HIV-1-positive individuals.
    Song H; Chu Y; Zhang H; Wang X; Zhang T; Qiu M; Wu H; Wu Z
    Scand J Immunol; 2013 Oct; 78(4):357-70. PubMed ID: 23808939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China.
    Wang S; Nie J; Wang Y
    Virus Res; 2011 Jan; 155(1):137-46. PubMed ID: 20875470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-neutralizing antibody profile of Chinese HIV-1-infected individuals and the viral envelope features from elite neutralizers.
    Ren C; Liu S; Li Y; Zhuang M; Yu H; Wang J; Sun F; Li D; Zhang H; Liu W; Liang S; Zhong P; Ling H
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):472-80. PubMed ID: 25202919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.
    Malherbe DC; Pissani F; Sather DN; Guo B; Pandey S; Sutton WF; Stuart AB; Robins H; Park B; Krebs SJ; Schuman JT; Kalams S; Hessell AJ; Haigwood NL
    J Virol; 2014 Nov; 88(22):12949-67. PubMed ID: 25210191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization breadth and potency of serum derived from recently human immunodeficiency virus type 1-infected Thai individuals.
    Chaitaveep N; Utachee P; Chuenchitra T; Karasavvan N; Takeda N; Kameoka M
    Microbes Infect; 2016 May; 18(5):346-53. PubMed ID: 26774333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.
    Hraber P; Korber BT; Lapedes AS; Bailer RT; Seaman MS; Gao H; Greene KM; McCutchan F; Williamson C; Kim JH; Tovanabutra S; Hahn BH; Swanstrom R; Thomson MM; Gao F; Harris L; Giorgi E; Hengartner N; Bhattacharya T; Mascola JR; Montefiori DC
    J Virol; 2014 Nov; 88(21):12623-43. PubMed ID: 25142591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.
    Mikell I; Stamatatos L
    PLoS One; 2012; 7(11):e49610. PubMed ID: 23152926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India.
    Hussain SI; Panneerselvam N; Solomon S; Solomon SS; Adam K; Chandrasekaran E; Montefiori DC; Pachamuthu B
    J Int Assoc Provid AIDS Care; 2017; 16(2):201-208. PubMed ID: 23422744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.
    van Gils MJ; Edo-Matas D; Schweighardt B; Wrin T; Schuitemaker H
    J Gen Virol; 2010 Jan; 91(Pt 1):250-8. PubMed ID: 19793903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
    Hraber P; Seaman MS; Bailer RT; Mascola JR; Montefiori DC; Korber BT
    AIDS; 2014 Jan; 28(2):163-9. PubMed ID: 24361678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.
    Medina-Ramírez M; Sánchez-Merino V; Sánchez-Palomino S; Merino-Mansilla A; Ferreira CB; Pérez I; González N; Alvarez A; Alcocer-González JM; García F; Gatell JM; Alcamí J; Yuste E
    J Virol; 2011 Jun; 85(12):5804-13. PubMed ID: 21471239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.